Literature DB >> 27053231

EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: disease mongering or call to action?

Elisabetta Bugianesi1.   

Abstract

Entities:  

Keywords:  Cost-effectiveness; Fatty liver; Guidelines; Screening

Mesh：

Year:  2016        PMID： 27053231     DOI： 10.1007/s00125-016-3930-7

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  12 in total

1.  Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study.

Authors:  Raymond Kwok; Kai Chow Choi; Grace Lai-Hung Wong; Yuying Zhang; Henry Lik-Yuen Chan; Andrea On-Yan Luk; Sally She-Ting Shu; Anthony Wing-Hung Chan; Ming-Wai Yeung; Juliana Chung-Ngor Chan; Alice Pik-Shan Kong; Vincent Wai-Sun Wong
Journal:  Gut       Date:  2015-04-14       Impact factor: 23.059

Review 2.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.

Authors:  Siddharth Singh; Alina M Allen; Zhen Wang; Larry J Prokop; Mohammad H Murad; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2014-04-24       Impact factor: 11.382

Review 3.  Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation.

Authors:  Catriona Crossan; Emmanuel A Tsochatzis; Louise Longworth; Kurinchi Gurusamy; Brian Davidson; Manuel Rodríguez-Perálvarez; Konstantinos Mantzoukis; Julia O'Brien; Evangelos Thalassinos; Vassilios Papastergiou; Andrew Burroughs
Journal:  Health Technol Assess       Date:  2015-01       Impact factor: 4.014

4.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

Authors: 
Journal:  Diabetologia       Date:  2016-06       Impact factor: 10.122

Review 5.  A 360-degree overview of paediatric NAFLD: recent insights.

Authors:  Valerio Nobili; Gianluca Svegliati-Baroni; Anna Alisi; Luca Miele; Luca Valenti; Pietro Vajro
Journal:  J Hepatol       Date:  2012-12-10       Impact factor: 25.083

6.  Updated definitions of healthy ranges for serum alanine aminotransferase levels.

Authors:  Daniele Prati; Emanuela Taioli; Alberto Zanella; Emanuela Della Torre; Sonia Butelli; Emanuela Del Vecchio; Luciana Vianello; Francesco Zanuso; Fulvio Mozzi; Silvano Milani; Dario Conte; Massimo Colombo; Girolamo Sirchia
Journal:  Ann Intern Med       Date:  2002-07-02       Impact factor: 25.391

Review 7.  Epidemiology and natural history of patients with NAFLD.

Authors:  Neeraj Bhala; Ramy Younes; Elisabetta Bugianesi
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

8.  SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease.

Authors:  Jeffrey B Schwimmer; Winston Dunn; Gregory J Norman; Perrie E Pardee; Michael S Middleton; Nanda Kerkar; Claude B Sirlin
Journal:  Gastroenterology       Date:  2010-01-11       Impact factor: 22.682

Review 9.  Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.

Authors:  Hannele Yki-Järvinen
Journal:  Lancet Diabetes Endocrinol       Date:  2014-04-07       Impact factor: 32.069

10.  Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis.

Authors:  Kathleen E Corey; Matthew J Klebanoff; Angela C Tramontano; Raymond T Chung; Chin Hur
Journal:  Dig Dis Sci       Date:  2016-01-29       Impact factor: 3.199
View more
  7 in total

Review 1.  Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome.

Authors:  Christoph Grander; Felix Grabherr; Alexander R Moschen; Herbert Tilg
Journal:  Visc Med       Date:  2016-09-16

2.  Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study.

Authors:  Abdel Aziz Shaheen; Kiarash Riazi; Alexandra Medellin; Deepak Bhayana; Gilaad G Kaplan; Jason Jiang; Roy Park; Wendy Schaufert; Kelly W Burak; Monica Sargious; Mark G Swain
Journal:  CMAJ Open       Date:  2020-05-15

Review 3.  Imaging of hepatocellular carcinoma and image guided therapies - how we do it.

Authors:  Jonathon Willatt; Julie A Ruma; Shadi F Azar; Nara L Dasika; F Syed
Journal:  Cancer Imaging       Date:  2017-03-04       Impact factor: 3.909

Review 4.  Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis.

Authors:  Sergio Quesada-Vázquez; Gerard Aragonès; Josep M Del Bas; Xavier Escoté
Journal:  Cells       Date:  2020-01-10       Impact factor: 6.600

5.  FABP4 and MMP9 levels identified as predictive factors for poor prognosis in patients with nonalcoholic fatty liver using data mining approaches and gene expression analysis.

Authors:  Audrey Coilly; Christophe Desterke; Catherine Guettier; Didier Samuel; Franck Chiappini
Journal:  Sci Rep       Date:  2019-12-24       Impact factor: 4.379

Review 6.  Dietary Patterns and Components in Nonalcoholic Fatty Liver Disease (NAFLD): What Key Messages Can Health Care Providers Offer?

Authors:  Kiarash Riazi; Maitreyi Raman; Lorian Taylor; Mark G Swain; Abdel Aziz Shaheen
Journal:  Nutrients       Date:  2019-11-26       Impact factor: 5.717

Review 7.  Detection of Early Disease Risk Factors Associated with Metabolic Syndrome: A New Era with the NMR Metabolomics Assessment.

Authors:  Julia Hernandez-Baixauli; Sergio Quesada-Vázquez; Roger Mariné-Casadó; Katherine Gil Cardoso; Antoni Caimari; Josep M Del Bas; Xavier Escoté; Laura Baselga-Escudero
Journal:  Nutrients       Date:  2020-03-18       Impact factor: 5.717
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.